Wire · opportunities
How a 63-Patient Trial Delivered an FDA Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 August 2026 · Fusion42 review
The FDA approved Pasatru (garetosmab-grts), a monoclonal antibody targeting Activin A, for treating fibrodysplasia ossificans progressiva (FOP) based on a 63-patient phase 3 trial showing significant reduction in new bone lesions and clinician-assessed flare-ups, marking a major advance for this ultra-rare disease.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 19 Aug 2026 and 31 Aug 2026.
◆ ◆ The Wire takeaway
You have a narrow regulatory window to prove highly targeted therapies in rare diseases with very small trials. Rapidly adopting imaging endpoints could accelerate your path to approval and market entry.
◆ Coverage
8 sources · first reported 19 Aug 2026 · latest 31 Aug 2026
◆ Topics